Angiotensin converting enzyme inhibitors for cancer treatment?

被引：78

作者：

Lindberg, H ^{[1
]}

Nielsen, D ^{[1
]}

Jensen, BV ^{[1
]}

Eriksen, J ^{[1
]}

Skovsgaard, T ^{[1
]}

机构：

[1] Univ Copenhagen, Herlev Hosp, Dept Oncol 54B1, DK-2730 Herlev, Denmark

来源：

ACTA ONCOLOGICA | 2004年 / 43卷 / 02期

关键词：

D O I：

10.1080/02841860310022346

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiotensin converting enzyme inhibitors (ACEi) prescribed for cardiovascular and renal disease since 1980 are widely atoxic and several experimental studies and one epidemiological study have demonstrated an effect of ACEi on cancer. ACEi has the effect of modifying gene expression; inhibiting proliferation and invasion of cancer cells; reducing endothelial cell migration and angiogenesis in vitro, whereas tumour growth and metastasis were inhibited in vivo. Several mechanisms of action are possible but inhibition of matrix metalloprotease activity, reduced expression of vascular endothelial growth factor and interference with the renin-angiotensin system were demonstrated by the experimental studies. In this paper we review the laboratory investigations and epidemiological studies on the anti-cancer actions of ACEi and present a summary of the evidence regarding the potential use of ACEi in cancer treatment.

引用

页码：142 / 152

页数：11

共 69 条

[1] Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model [J].

Alves, F ;

Borchers, U ;

Padge, B ;

Augustin, H ;

Nebendahl, K ;

Klöppel, G ;

Tietze, LF .

CANCER LETTERS, 2001, 165 (02) :161-170

[2]

Anderson IC, 1996, CANCER RES, V56, P715

[3] MMP inhibitors: experimental and clinical studies [J].

Belotti, D ;

Paganoni, P ;

Giavazzi, R .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1999, 14 (04) :232-238

[4]

BISSETT D, 2002, P AN M AM SOC CLIN, V21, pA296

[5] Extracellular matrix signaling: integration of form and function in normal and malignant cells [J].

Boudreau, N ;

Bissell, MJ .

CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (05) :640-646

[6] Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial [J].

Bramhall, SR ;

Hallissey, MT ;

Whiting, J ;

Scholefield, J ;

Tierney, G ;

Stuart, RC ;

Hawkins, RE ;

McCulloch, P ;

Maughan, T ;

Brown, PD ;

Baillet, M .

BRITISH JOURNAL OF CANCER, 2002, 86 (12) :1864-1870

[7] A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].

Bramhall, SR ;

Schulz, J ;

Nemunaitis, J ;

Brown, PD ;

Baillet, M ;

Buckels, JAC .

BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167

[8] Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial [J].

Bramhall, SR ;

Rosemurgy, A ;

Brown, PD ;

Bowry, C ;

Buckels, JAC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) :3447-3455

[9] Matrix metalloproteinase inhibition: A review of anti-tumour activity [J].

Brown, PD ;

Giavazzi, R .

ANNALS OF ONCOLOGY, 1995, 6 (10) :967-974

[10] Clinical studies with matrix metalloproteinase inhibitors [J].

Brown, PD .

APMIS, 1999, 107 (01) :174-180

← 1 2 3 4 5 6 7 →